Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy

Int J Mol Sci. 2018 Mar 10;19(3):799. doi: 10.3390/ijms19030799.

Abstract

Despite several therapeutic advances, malignant melanoma still remains a fatal disease for which novel and long-term curative treatments are needed. The successful development of innovative therapies strongly depends on the availability of appropriate pre-clinical models. For this purpose, several mouse models holding the promise to provide insight into molecular biology and clinical behavior of melanoma have been generated. The most relevant ones and their contribution for the advancement of therapeutic approaches for the treatment of human melanoma patients will be here summarized. However, as models, mice do not recapitulate all the features of human melanoma, thus their strengths and weaknesses need to be carefully identified and considered for the translation of the results into the human clinics. In this panorama, the concept of comparative oncology acquires a priceless value. The revolutionary importance of spontaneous canine melanoma as a translational model for the pre-clinical investigation of melanoma progression and treatment will be here discussed, with a special consideration to the development of innovative immunotherapeutic approaches.

Keywords: CSPG4; canine melanoma; comparative oncology; immunotherapy; melanoma; pre-clinical models.

Publication types

  • Review

MeSH terms

  • Animals
  • Disease Models, Animal*
  • Dog Diseases / drug therapy
  • Dog Diseases / therapy*
  • Dogs
  • Drug Evaluation, Preclinical / methods*
  • Drug Evaluation, Preclinical / standards
  • Humans
  • Immunotherapy / methods*
  • Immunotherapy / standards
  • Melanoma / drug therapy
  • Melanoma / therapy*
  • Mice